nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD5—eyelid—skin cancer	0.0517	0.177	CbGeAlD
L-DOPA—Mimosine—TYR—skin cancer	0.0237	0.923	CrCbGaD
L-DOPA—SLC7A8—skin epidermis—skin cancer	0.0194	0.0665	CbGeAlD
L-DOPA—DDC—nerve—skin cancer	0.0143	0.049	CbGeAlD
L-DOPA—PSIP1—neck—skin cancer	0.0141	0.0483	CbGeAlD
L-DOPA—SLC7A8—hair follicle—skin cancer	0.0139	0.0474	CbGeAlD
L-DOPA—DRD1—nerve—skin cancer	0.0105	0.036	CbGeAlD
L-DOPA—SLC7A8—neck—skin cancer	0.0093	0.0318	CbGeAlD
L-DOPA—PSIP1—mammalian vulva—skin cancer	0.00833	0.0285	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—skin cancer	0.0074	0.0253	CbGeAlD
L-DOPA—SLC7A5—nipple—skin cancer	0.00729	0.0249	CbGeAlD
L-DOPA—PSIP1—female reproductive system—skin cancer	0.00713	0.0244	CbGeAlD
L-DOPA—DRD2—nerve—skin cancer	0.00622	0.0213	CbGeAlD
L-DOPA—SLC7A8—skin of body—skin cancer	0.00602	0.0206	CbGeAlD
L-DOPA—PSIP1—head—skin cancer	0.00596	0.0204	CbGeAlD
L-DOPA—SLC16A10—nipple—skin cancer	0.00558	0.0191	CbGeAlD
L-DOPA—SLC16A10—neck—skin cancer	0.00552	0.0189	CbGeAlD
L-DOPA—SLC7A5—connective tissue—skin cancer	0.00517	0.0177	CbGeAlD
L-DOPA—SLC7A5—epithelium—skin cancer	0.00491	0.0168	CbGeAlD
L-DOPA—SLC7A8—female reproductive system—skin cancer	0.0047	0.0161	CbGeAlD
L-DOPA—SLC7A5—skin of body—skin cancer	0.00467	0.016	CbGeAlD
L-DOPA—SLC7A5—mammalian vulva—skin cancer	0.00426	0.0146	CbGeAlD
L-DOPA—PSIP1—lymph node—skin cancer	0.00417	0.0143	CbGeAlD
L-DOPA—SLC15A1—epithelium—skin cancer	0.00407	0.0139	CbGeAlD
L-DOPA—DDC—female reproductive system—skin cancer	0.00407	0.0139	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—skin cancer	0.00406	0.0139	CbGeAlD
L-DOPA—SLC7A8—head—skin cancer	0.00393	0.0134	CbGeAlD
L-DOPA—DRD5—female reproductive system—skin cancer	0.00391	0.0134	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—skin cancer	0.00378	0.0129	CbGeAlD
L-DOPA—SLC16A10—epithelium—skin cancer	0.00376	0.0128	CbGeAlD
L-DOPA—SLC7A5—female reproductive system—skin cancer	0.00364	0.0125	CbGeAlD
L-DOPA—SLC15A1—mammalian vulva—skin cancer	0.00353	0.0121	CbGeAlD
L-DOPA—DRD3—head—skin cancer	0.00349	0.0119	CbGeAlD
L-DOPA—DDC—head—skin cancer	0.0034	0.0116	CbGeAlD
L-DOPA—DRD5—head—skin cancer	0.00327	0.0112	CbGeAlD
L-DOPA—SLC16A10—mammalian vulva—skin cancer	0.00326	0.0111	CbGeAlD
L-DOPA—SLC7A5—head—skin cancer	0.00304	0.0104	CbGeAlD
L-DOPA—SLC16A10—lymphoid tissue—skin cancer	0.00289	0.0099	CbGeAlD
L-DOPA—SLC16A10—female reproductive system—skin cancer	0.00279	0.00955	CbGeAlD
L-DOPA—SLC7A8—lymph node—skin cancer	0.00275	0.00941	CbGeAlD
L-DOPA—DRD1—head—skin cancer	0.0025	0.00854	CbGeAlD
L-DOPA—DDC—lymph node—skin cancer	0.00238	0.00814	CbGeAlD
L-DOPA—SLC7A5—lymph node—skin cancer	0.00213	0.00729	CbGeAlD
L-DOPA—SLC16A10—lymph node—skin cancer	0.00163	0.00558	CbGeAlD
L-DOPA—DRD2—head—skin cancer	0.00148	0.00505	CbGeAlD
L-DOPA—Flushing—Bleomycin—skin cancer	0.00128	0.00233	CcSEcCtD
L-DOPA—Neuropathy peripheral—Temozolomide—skin cancer	0.00127	0.00231	CcSEcCtD
L-DOPA—Urinary tract infection—Temozolomide—skin cancer	0.00126	0.00229	CcSEcCtD
L-DOPA—Insomnia—Imiquimod—skin cancer	0.00125	0.00227	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00124	0.00226	CcSEcCtD
L-DOPA—Paraesthesia—Imiquimod—skin cancer	0.00124	0.00225	CcSEcCtD
L-DOPA—Dyspnoea—Imiquimod—skin cancer	0.00123	0.00224	CcSEcCtD
L-DOPA—Somnolence—Imiquimod—skin cancer	0.00122	0.00223	CcSEcCtD
L-DOPA—Alopecia—Bleomycin—skin cancer	0.00122	0.00222	CcSEcCtD
L-DOPA—Dyspepsia—Imiquimod—skin cancer	0.00121	0.00221	CcSEcCtD
L-DOPA—Decreased appetite—Imiquimod—skin cancer	0.0012	0.00218	CcSEcCtD
L-DOPA—Hot flush—Docetaxel—skin cancer	0.00119	0.00218	CcSEcCtD
L-DOPA—Flushing—Dactinomycin—skin cancer	0.00119	0.00217	CcSEcCtD
L-DOPA—Hypersensitivity—Vemurafenib—skin cancer	0.00119	0.00217	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Imiquimod—skin cancer	0.00119	0.00217	CcSEcCtD
L-DOPA—Fatigue—Imiquimod—skin cancer	0.00119	0.00216	CcSEcCtD
L-DOPA—Menopausal symptoms—Docetaxel—skin cancer	0.00118	0.00216	CcSEcCtD
L-DOPA—Pain—Imiquimod—skin cancer	0.00118	0.00215	CcSEcCtD
L-DOPA—Acute coronary syndrome—Fluorouracil—skin cancer	0.00118	0.00214	CcSEcCtD
L-DOPA—Neuropathy peripheral—Fluorouracil—skin cancer	0.00117	0.00213	CcSEcCtD
L-DOPA—Myocardial infarction—Fluorouracil—skin cancer	0.00117	0.00213	CcSEcCtD
L-DOPA—Dermatitis bullous—Docetaxel—skin cancer	0.00117	0.00213	CcSEcCtD
L-DOPA—Haemoglobin—Temozolomide—skin cancer	0.00117	0.00213	CcSEcCtD
L-DOPA—Haemorrhage—Temozolomide—skin cancer	0.00116	0.00212	CcSEcCtD
L-DOPA—Urinary tract infection—Fluorouracil—skin cancer	0.00116	0.00211	CcSEcCtD
L-DOPA—Asthenia—Vemurafenib—skin cancer	0.00116	0.00211	CcSEcCtD
L-DOPA—Hypoaesthesia—Temozolomide—skin cancer	0.00116	0.00211	CcSEcCtD
L-DOPA—Hallucination—Temozolomide—skin cancer	0.00116	0.00211	CcSEcCtD
L-DOPA—Urinary tract disorder—Temozolomide—skin cancer	0.00115	0.00209	CcSEcCtD
L-DOPA—Pruritus—Vemurafenib—skin cancer	0.00114	0.00208	CcSEcCtD
L-DOPA—Urethral disorder—Temozolomide—skin cancer	0.00114	0.00208	CcSEcCtD
L-DOPA—Alopecia—Dactinomycin—skin cancer	0.00113	0.00207	CcSEcCtD
L-DOPA—Feeling abnormal—Imiquimod—skin cancer	0.00113	0.00207	CcSEcCtD
L-DOPA—Gastrointestinal pain—Imiquimod—skin cancer	0.00113	0.00205	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.00112	0.00204	CcSEcCtD
L-DOPA—Pain in extremity—Docetaxel—skin cancer	0.00112	0.00204	CcSEcCtD
L-DOPA—Agranulocytosis—Fluorouracil—skin cancer	0.00111	0.00203	CcSEcCtD
L-DOPA—Ill-defined disorder—Bleomycin—skin cancer	0.00111	0.00203	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—skin cancer	0.00111	0.0431	CrCbGaD
L-DOPA—Anaemia—Bleomycin—skin cancer	0.00111	0.00202	CcSEcCtD
L-DOPA—Diarrhoea—Vemurafenib—skin cancer	0.0011	0.00201	CcSEcCtD
L-DOPA—Urticaria—Imiquimod—skin cancer	0.00109	0.00199	CcSEcCtD
L-DOPA—Abdominal pain—Imiquimod—skin cancer	0.00109	0.00198	CcSEcCtD
L-DOPA—Malaise—Bleomycin—skin cancer	0.00108	0.00197	CcSEcCtD
L-DOPA—Flushing—Temozolomide—skin cancer	0.00108	0.00196	CcSEcCtD
L-DOPA—Haemoglobin—Fluorouracil—skin cancer	0.00108	0.00196	CcSEcCtD
L-DOPA—Leukopenia—Bleomycin—skin cancer	0.00107	0.00196	CcSEcCtD
L-DOPA—Rhinitis—Fluorouracil—skin cancer	0.00107	0.00196	CcSEcCtD
L-DOPA—Haemorrhage—Fluorouracil—skin cancer	0.00107	0.00195	CcSEcCtD
L-DOPA—Dizziness—Vemurafenib—skin cancer	0.00107	0.00195	CcSEcCtD
L-DOPA—Hypoaesthesia—Fluorouracil—skin cancer	0.00106	0.00194	CcSEcCtD
L-DOPA—CYP2D6—female reproductive system—skin cancer	0.00106	0.00363	CbGeAlD
L-DOPA—Ataxia—Docetaxel—skin cancer	0.00105	0.00191	CcSEcCtD
L-DOPA—Cough—Bleomycin—skin cancer	0.00105	0.00191	CcSEcCtD
L-DOPA—Ill-defined disorder—Dactinomycin—skin cancer	0.00104	0.00189	CcSEcCtD
L-DOPA—Anaemia—Dactinomycin—skin cancer	0.00103	0.00188	CcSEcCtD
L-DOPA—Vomiting—Vemurafenib—skin cancer	0.00103	0.00187	CcSEcCtD
L-DOPA—Alopecia—Temozolomide—skin cancer	0.00103	0.00187	CcSEcCtD
L-DOPA—Chest pain—Bleomycin—skin cancer	0.00102	0.00186	CcSEcCtD
L-DOPA—Orthostatic hypotension—Docetaxel—skin cancer	0.00102	0.00186	CcSEcCtD
L-DOPA—Rash—Vemurafenib—skin cancer	0.00102	0.00186	CcSEcCtD
L-DOPA—Mental disorder—Temozolomide—skin cancer	0.00102	0.00185	CcSEcCtD
L-DOPA—Dermatitis—Vemurafenib—skin cancer	0.00102	0.00185	CcSEcCtD
L-DOPA—Hypersensitivity—Imiquimod—skin cancer	0.00101	0.00185	CcSEcCtD
L-DOPA—Headache—Vemurafenib—skin cancer	0.00101	0.00184	CcSEcCtD
L-DOPA—Discomfort—Bleomycin—skin cancer	0.00101	0.00184	CcSEcCtD
L-DOPA—Malaise—Dactinomycin—skin cancer	0.00101	0.00184	CcSEcCtD
L-DOPA—Cramp muscle—Docetaxel—skin cancer	0.00101	0.00183	CcSEcCtD
L-DOPA—Leukopenia—Dactinomycin—skin cancer	0.001	0.00182	CcSEcCtD
L-DOPA—Nasopharyngitis—Docetaxel—skin cancer	0.000998	0.00182	CcSEcCtD
L-DOPA—Dysgeusia—Temozolomide—skin cancer	0.00099	0.0018	CcSEcCtD
L-DOPA—Asthenia—Imiquimod—skin cancer	0.000988	0.0018	CcSEcCtD
L-DOPA—Confusional state—Bleomycin—skin cancer	0.000986	0.0018	CcSEcCtD
L-DOPA—Oedema—Bleomycin—skin cancer	0.000978	0.00178	CcSEcCtD
L-DOPA—Back pain—Temozolomide—skin cancer	0.000978	0.00178	CcSEcCtD
L-DOPA—Pruritus—Imiquimod—skin cancer	0.000974	0.00178	CcSEcCtD
L-DOPA—Dysphagia—Docetaxel—skin cancer	0.000965	0.00176	CcSEcCtD
L-DOPA—Nausea—Vemurafenib—skin cancer	0.000959	0.00175	CcSEcCtD
L-DOPA—Thrombocytopenia—Bleomycin—skin cancer	0.000958	0.00175	CcSEcCtD
L-DOPA—Arrhythmia—Fluorouracil—skin cancer	0.000956	0.00174	CcSEcCtD
L-DOPA—Vision blurred—Temozolomide—skin cancer	0.000953	0.00174	CcSEcCtD
L-DOPA—Tremor—Temozolomide—skin cancer	0.000947	0.00173	CcSEcCtD
L-DOPA—Alopecia—Fluorouracil—skin cancer	0.000946	0.00172	CcSEcCtD
L-DOPA—Diarrhoea—Imiquimod—skin cancer	0.000942	0.00172	CcSEcCtD
L-DOPA—Discomfort—Dactinomycin—skin cancer	0.00094	0.00171	CcSEcCtD
L-DOPA—Angina pectoris—Docetaxel—skin cancer	0.00094	0.00171	CcSEcCtD
L-DOPA—Ill-defined disorder—Temozolomide—skin cancer	0.000938	0.00171	CcSEcCtD
L-DOPA—Anaemia—Temozolomide—skin cancer	0.000935	0.0017	CcSEcCtD
L-DOPA—Anorexia—Bleomycin—skin cancer	0.000932	0.0017	CcSEcCtD
L-DOPA—Agitation—Temozolomide—skin cancer	0.000929	0.00169	CcSEcCtD
L-DOPA—Angioedema—Temozolomide—skin cancer	0.000924	0.00168	CcSEcCtD
L-DOPA—Hypotension—Bleomycin—skin cancer	0.000914	0.00167	CcSEcCtD
L-DOPA—Oedema—Dactinomycin—skin cancer	0.000912	0.00166	CcSEcCtD
L-DOPA—Malaise—Temozolomide—skin cancer	0.000912	0.00166	CcSEcCtD
L-DOPA—Dizziness—Imiquimod—skin cancer	0.000911	0.00166	CcSEcCtD
L-DOPA—Leukopenia—Temozolomide—skin cancer	0.000905	0.00165	CcSEcCtD
L-DOPA—Palpitations—Temozolomide—skin cancer	0.000894	0.00163	CcSEcCtD
L-DOPA—Thrombocytopenia—Dactinomycin—skin cancer	0.000893	0.00163	CcSEcCtD
L-DOPA—CYP2D6—head—skin cancer	0.000887	0.00303	CbGeAlD
L-DOPA—Cough—Temozolomide—skin cancer	0.000882	0.00161	CcSEcCtD
L-DOPA—Paraesthesia—Bleomycin—skin cancer	0.000878	0.0016	CcSEcCtD
L-DOPA—Weight increased—Docetaxel—skin cancer	0.000878	0.0016	CcSEcCtD
L-DOPA—Vision blurred—Fluorouracil—skin cancer	0.000878	0.0016	CcSEcCtD
L-DOPA—Convulsion—Temozolomide—skin cancer	0.000876	0.0016	CcSEcCtD
L-DOPA—Vomiting—Imiquimod—skin cancer	0.000876	0.0016	CcSEcCtD
L-DOPA—Weight decreased—Docetaxel—skin cancer	0.000873	0.00159	CcSEcCtD
L-DOPA—Hypertension—Temozolomide—skin cancer	0.000873	0.00159	CcSEcCtD
L-DOPA—Dyspnoea—Bleomycin—skin cancer	0.000872	0.00159	CcSEcCtD
L-DOPA—Anorexia—Dactinomycin—skin cancer	0.00087	0.00159	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—skin cancer	0.000869	0.0339	CrCbGaD
L-DOPA—Rash—Imiquimod—skin cancer	0.000868	0.00158	CcSEcCtD
L-DOPA—Dermatitis—Imiquimod—skin cancer	0.000867	0.00158	CcSEcCtD
L-DOPA—Headache—Imiquimod—skin cancer	0.000863	0.00157	CcSEcCtD
L-DOPA—Anaemia—Fluorouracil—skin cancer	0.000861	0.00157	CcSEcCtD
L-DOPA—Anxiety—Temozolomide—skin cancer	0.000858	0.00156	CcSEcCtD
L-DOPA—Discomfort—Temozolomide—skin cancer	0.00085	0.00155	CcSEcCtD
L-DOPA—Decreased appetite—Bleomycin—skin cancer	0.00085	0.00155	CcSEcCtD
L-DOPA—Acute coronary syndrome—Docetaxel—skin cancer	0.000848	0.00155	CcSEcCtD
L-DOPA—Neuropathy peripheral—Docetaxel—skin cancer	0.000843	0.00154	CcSEcCtD
L-DOPA—Myocardial infarction—Docetaxel—skin cancer	0.000843	0.00154	CcSEcCtD
L-DOPA—Dry mouth—Temozolomide—skin cancer	0.000842	0.00153	CcSEcCtD
L-DOPA—Pain—Bleomycin—skin cancer	0.000837	0.00152	CcSEcCtD
L-DOPA—Leukopenia—Fluorouracil—skin cancer	0.000834	0.00152	CcSEcCtD
L-DOPA—Confusional state—Temozolomide—skin cancer	0.000832	0.00152	CcSEcCtD
L-DOPA—Oedema—Temozolomide—skin cancer	0.000825	0.0015	CcSEcCtD
L-DOPA—Nausea—Imiquimod—skin cancer	0.000818	0.00149	CcSEcCtD
L-DOPA—Thrombocytopenia—Temozolomide—skin cancer	0.000808	0.00147	CcSEcCtD
L-DOPA—Convulsion—Fluorouracil—skin cancer	0.000807	0.00147	CcSEcCtD
L-DOPA—Feeling abnormal—Bleomycin—skin cancer	0.000806	0.00147	CcSEcCtD
L-DOPA—Agranulocytosis—Docetaxel—skin cancer	0.000803	0.00146	CcSEcCtD
L-DOPA—Hyperhidrosis—Temozolomide—skin cancer	0.000798	0.00145	CcSEcCtD
L-DOPA—Chest pain—Fluorouracil—skin cancer	0.000793	0.00145	CcSEcCtD
L-DOPA—Decreased appetite—Dactinomycin—skin cancer	0.000793	0.00145	CcSEcCtD
L-DOPA—Fatigue—Dactinomycin—skin cancer	0.000787	0.00143	CcSEcCtD
L-DOPA—Anorexia—Temozolomide—skin cancer	0.000787	0.00143	CcSEcCtD
L-DOPA—Discomfort—Fluorouracil—skin cancer	0.000784	0.00143	CcSEcCtD
L-DOPA—Pain—Dactinomycin—skin cancer	0.00078	0.00142	CcSEcCtD
L-DOPA—Urticaria—Bleomycin—skin cancer	0.000777	0.00142	CcSEcCtD
L-DOPA—Haemoglobin—Docetaxel—skin cancer	0.000776	0.00142	CcSEcCtD
L-DOPA—Rhinitis—Docetaxel—skin cancer	0.000774	0.00141	CcSEcCtD
L-DOPA—Haemorrhage—Docetaxel—skin cancer	0.000772	0.00141	CcSEcCtD
L-DOPA—Hypoaesthesia—Docetaxel—skin cancer	0.000769	0.0014	CcSEcCtD
L-DOPA—Confusional state—Fluorouracil—skin cancer	0.000767	0.0014	CcSEcCtD
L-DOPA—Urinary tract disorder—Docetaxel—skin cancer	0.000763	0.00139	CcSEcCtD
L-DOPA—Oedema—Fluorouracil—skin cancer	0.00076	0.00139	CcSEcCtD
L-DOPA—Urethral disorder—Docetaxel—skin cancer	0.000757	0.00138	CcSEcCtD
L-DOPA—Feeling abnormal—Dactinomycin—skin cancer	0.000752	0.00137	CcSEcCtD
L-DOPA—Insomnia—Temozolomide—skin cancer	0.000746	0.00136	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dactinomycin—skin cancer	0.000746	0.00136	CcSEcCtD
L-DOPA—Thrombocytopenia—Fluorouracil—skin cancer	0.000744	0.00136	CcSEcCtD
L-DOPA—Paraesthesia—Temozolomide—skin cancer	0.000741	0.00135	CcSEcCtD
L-DOPA—Dyspnoea—Temozolomide—skin cancer	0.000736	0.00134	CcSEcCtD
L-DOPA—Somnolence—Temozolomide—skin cancer	0.000734	0.00134	CcSEcCtD
L-DOPA—Dyspepsia—Temozolomide—skin cancer	0.000726	0.00132	CcSEcCtD
L-DOPA—Anorexia—Fluorouracil—skin cancer	0.000725	0.00132	CcSEcCtD
L-DOPA—Abdominal pain—Dactinomycin—skin cancer	0.000721	0.00131	CcSEcCtD
L-DOPA—Hypersensitivity—Bleomycin—skin cancer	0.000721	0.00131	CcSEcCtD
L-DOPA—Decreased appetite—Temozolomide—skin cancer	0.000717	0.00131	CcSEcCtD
L-DOPA—Flushing—Docetaxel—skin cancer	0.000717	0.00131	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Temozolomide—skin cancer	0.000712	0.0013	CcSEcCtD
L-DOPA—Fatigue—Temozolomide—skin cancer	0.000711	0.0013	CcSEcCtD
L-DOPA—Hypotension—Fluorouracil—skin cancer	0.00071	0.00129	CcSEcCtD
L-DOPA—Pain—Temozolomide—skin cancer	0.000706	0.00129	CcSEcCtD
L-DOPA—Constipation—Temozolomide—skin cancer	0.000706	0.00129	CcSEcCtD
L-DOPA—Asthenia—Bleomycin—skin cancer	0.000702	0.00128	CcSEcCtD
L-DOPA—Pruritus—Bleomycin—skin cancer	0.000692	0.00126	CcSEcCtD
L-DOPA—Arrhythmia—Docetaxel—skin cancer	0.00069	0.00126	CcSEcCtD
L-DOPA—Insomnia—Fluorouracil—skin cancer	0.000688	0.00125	CcSEcCtD
L-DOPA—Paraesthesia—Fluorouracil—skin cancer	0.000683	0.00124	CcSEcCtD
L-DOPA—Alopecia—Docetaxel—skin cancer	0.000683	0.00124	CcSEcCtD
L-DOPA—Feeling abnormal—Temozolomide—skin cancer	0.00068	0.00124	CcSEcCtD
L-DOPA—Dyspnoea—Fluorouracil—skin cancer	0.000678	0.00124	CcSEcCtD
L-DOPA—Mental disorder—Docetaxel—skin cancer	0.000677	0.00123	CcSEcCtD
L-DOPA—Somnolence—Fluorouracil—skin cancer	0.000676	0.00123	CcSEcCtD
L-DOPA—Gastrointestinal pain—Temozolomide—skin cancer	0.000675	0.00123	CcSEcCtD
L-DOPA—Hypersensitivity—Dactinomycin—skin cancer	0.000672	0.00123	CcSEcCtD
L-DOPA—Dyspepsia—Fluorouracil—skin cancer	0.000669	0.00122	CcSEcCtD
L-DOPA—Decreased appetite—Fluorouracil—skin cancer	0.000661	0.0012	CcSEcCtD
L-DOPA—Dysgeusia—Docetaxel—skin cancer	0.000658	0.0012	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000656	0.0012	CcSEcCtD
L-DOPA—Urticaria—Temozolomide—skin cancer	0.000656	0.00119	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—skin cancer	0.000655	0.00119	CcSEcCtD
L-DOPA—Abdominal pain—Temozolomide—skin cancer	0.000652	0.00119	CcSEcCtD
L-DOPA—Back pain—Docetaxel—skin cancer	0.00065	0.00119	CcSEcCtD
L-DOPA—Pain—Fluorouracil—skin cancer	0.00065	0.00119	CcSEcCtD
L-DOPA—Muscle spasms—Docetaxel—skin cancer	0.000646	0.00118	CcSEcCtD
L-DOPA—Feeling abnormal—Fluorouracil—skin cancer	0.000627	0.00114	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—skin cancer	0.000624	0.00114	CcSEcCtD
L-DOPA—Vomiting—Bleomycin—skin cancer	0.000622	0.00113	CcSEcCtD
L-DOPA—Anaemia—Docetaxel—skin cancer	0.000621	0.00113	CcSEcCtD
L-DOPA—Rash—Bleomycin—skin cancer	0.000617	0.00112	CcSEcCtD
L-DOPA—Dermatitis—Bleomycin—skin cancer	0.000616	0.00112	CcSEcCtD
L-DOPA—Hypersensitivity—Temozolomide—skin cancer	0.000608	0.00111	CcSEcCtD
L-DOPA—Urticaria—Fluorouracil—skin cancer	0.000604	0.0011	CcSEcCtD
L-DOPA—Syncope—Docetaxel—skin cancer	0.000603	0.0011	CcSEcCtD
L-DOPA—Leukopenia—Docetaxel—skin cancer	0.000602	0.0011	CcSEcCtD
L-DOPA—Palpitations—Docetaxel—skin cancer	0.000594	0.00108	CcSEcCtD
L-DOPA—Asthenia—Temozolomide—skin cancer	0.000592	0.00108	CcSEcCtD
L-DOPA—Loss of consciousness—Docetaxel—skin cancer	0.000591	0.00108	CcSEcCtD
L-DOPA—Cough—Docetaxel—skin cancer	0.000587	0.00107	CcSEcCtD
L-DOPA—Pruritus—Temozolomide—skin cancer	0.000584	0.00106	CcSEcCtD
L-DOPA—Convulsion—Docetaxel—skin cancer	0.000583	0.00106	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—PTCH2—skin cancer	0.000581	0.00436	CbGpPWpGaD
L-DOPA—Nausea—Bleomycin—skin cancer	0.000581	0.00106	CcSEcCtD
L-DOPA—Hypertension—Docetaxel—skin cancer	0.000581	0.00106	CcSEcCtD
L-DOPA—Vomiting—Dactinomycin—skin cancer	0.00058	0.00106	CcSEcCtD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00058	0.00435	CbGpPWpGaD
L-DOPA—Rash—Dactinomycin—skin cancer	0.000575	0.00105	CcSEcCtD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000574	0.0043	CbGpPWpGaD
L-DOPA—Chest pain—Docetaxel—skin cancer	0.000572	0.00104	CcSEcCtD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000572	0.00429	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—MC1R—skin cancer	0.00057	0.00427	CbGpPWpGaD
L-DOPA—Diarrhoea—Temozolomide—skin cancer	0.000565	0.00103	CcSEcCtD
L-DOPA—Hypersensitivity—Fluorouracil—skin cancer	0.00056	0.00102	CcSEcCtD
L-DOPA—Dry mouth—Docetaxel—skin cancer	0.00056	0.00102	CcSEcCtD
L-DOPA—SLC7A5—Cell surface interactions at the vascular wall—KRAS—skin cancer	0.000555	0.00416	CbGpPWpGaD
L-DOPA—Confusional state—Docetaxel—skin cancer	0.000553	0.00101	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000552	0.00414	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ENO2—skin cancer	0.000549	0.00412	CbGpPWpGaD
L-DOPA—PSIP1—Disease—SHH—skin cancer	0.000549	0.00412	CbGpPWpGaD
L-DOPA—Oedema—Docetaxel—skin cancer	0.000549	0.001	CcSEcCtD
L-DOPA—Dizziness—Temozolomide—skin cancer	0.000546	0.000995	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—skin cancer	0.000542	0.000988	CcSEcCtD
L-DOPA—SLC7A8—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.000541	0.00406	CbGpPWpGaD
L-DOPA—Shock—Docetaxel—skin cancer	0.00054	0.000984	CcSEcCtD
L-DOPA—Pruritus—Fluorouracil—skin cancer	0.000538	0.00098	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—skin cancer	0.000537	0.000979	CcSEcCtD
L-DOPA—Vomiting—Temozolomide—skin cancer	0.000525	0.000956	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—PTCH2—skin cancer	0.000523	0.00392	CbGpPWpGaD
L-DOPA—Anorexia—Docetaxel—skin cancer	0.000523	0.000953	CcSEcCtD
L-DOPA—Rash—Temozolomide—skin cancer	0.00052	0.000948	CcSEcCtD
L-DOPA—Diarrhoea—Fluorouracil—skin cancer	0.00052	0.000948	CcSEcCtD
L-DOPA—Dermatitis—Temozolomide—skin cancer	0.00052	0.000947	CcSEcCtD
L-DOPA—Headache—Temozolomide—skin cancer	0.000517	0.000942	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—PTCH2—skin cancer	0.000516	0.00387	CbGpPWpGaD
L-DOPA—Hypotension—Docetaxel—skin cancer	0.000513	0.000935	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—skin cancer	0.000503	0.000916	CcSEcCtD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000499	0.00374	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000497	0.00373	CbGpPWpGaD
L-DOPA—Insomnia—Docetaxel—skin cancer	0.000496	0.000905	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—skin cancer	0.000493	0.000898	CcSEcCtD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000492	0.00369	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00049	0.00368	CbGpPWpGaD
L-DOPA—Nausea—Temozolomide—skin cancer	0.00049	0.000893	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—skin cancer	0.000489	0.000892	CcSEcCtD
L-DOPA—DRD5—Signaling Pathways—RHOU—skin cancer	0.000489	0.00367	CbGpPWpGaD
L-DOPA—Somnolence—Docetaxel—skin cancer	0.000488	0.000889	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—skin cancer	0.000483	0.000881	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—skin cancer	0.000483	0.00088	CcSEcCtD
L-DOPA—Rash—Fluorouracil—skin cancer	0.000479	0.000874	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—skin cancer	0.000479	0.000873	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—skin cancer	0.000477	0.000869	CcSEcCtD
L-DOPA—Headache—Fluorouracil—skin cancer	0.000476	0.000868	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—skin cancer	0.000474	0.000864	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—skin cancer	0.000473	0.000862	CcSEcCtD
L-DOPA—SLC7A5—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.000472	0.00354	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—CDK4—skin cancer	0.000471	0.00353	CbGpPWpGaD
L-DOPA—Constipation—Docetaxel—skin cancer	0.000469	0.000855	CcSEcCtD
L-DOPA—Pain—Docetaxel—skin cancer	0.000469	0.000855	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—skin cancer	0.000452	0.000824	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—skin cancer	0.000452	0.000823	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—skin cancer	0.000449	0.000818	CcSEcCtD
L-DOPA—PSIP1—Disease—FOXO4—skin cancer	0.000448	0.00336	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000438	0.00328	CbGpPWpGaD
L-DOPA—Abdominal pain—Docetaxel—skin cancer	0.000434	0.000791	CcSEcCtD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000424	0.00318	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—MC1R—skin cancer	0.00042	0.00315	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—SHH—skin cancer	0.000406	0.00304	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTCH2—skin cancer	0.000404	0.00303	CbGpPWpGaD
L-DOPA—Hypersensitivity—Docetaxel—skin cancer	0.000404	0.000737	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—PTCH2—skin cancer	0.000395	0.00296	CbGpPWpGaD
L-DOPA—Asthenia—Docetaxel—skin cancer	0.000394	0.000718	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—skin cancer	0.000388	0.000708	CcSEcCtD
L-DOPA—DRD5—GPCR ligand binding—SMO—skin cancer	0.000385	0.00288	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—PTCH1—skin cancer	0.000385	0.00288	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000381	0.00286	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—MC1R—skin cancer	0.000378	0.00284	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000376	0.00282	CbGpPWpGaD
L-DOPA—Diarrhoea—Docetaxel—skin cancer	0.000375	0.000684	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000375	0.00281	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—PTGER4—skin cancer	0.000375	0.00281	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—MC1R—skin cancer	0.000373	0.0028	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000363	0.00272	CbGpPWpGaD
L-DOPA—Dizziness—Docetaxel—skin cancer	0.000363	0.000661	CcSEcCtD
L-DOPA—DRD4—Signaling Pathways—RHOU—skin cancer	0.000361	0.00271	CbGpPWpGaD
L-DOPA—Vomiting—Docetaxel—skin cancer	0.000349	0.000636	CcSEcCtD
L-DOPA—Rash—Docetaxel—skin cancer	0.000346	0.000631	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—skin cancer	0.000346	0.00063	CcSEcCtD
L-DOPA—Headache—Docetaxel—skin cancer	0.000344	0.000627	CcSEcCtD
L-DOPA—DDC—Metabolism—PLIN2—skin cancer	0.000342	0.00256	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000327	0.00245	CbGpPWpGaD
L-DOPA—Nausea—Docetaxel—skin cancer	0.000326	0.000594	CcSEcCtD
L-DOPA—DRD1—Signaling Pathways—RHOU—skin cancer	0.000325	0.00244	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000322	0.00242	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—MC1R—skin cancer	0.000322	0.00241	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RHOU—skin cancer	0.000321	0.0024	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ERCC2—skin cancer	0.000319	0.00239	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—SHH—skin cancer	0.0003	0.00225	CbGpPWpGaD
L-DOPA—PSIP1—Disease—TERT—skin cancer	0.000299	0.00224	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTCH2—skin cancer	0.000298	0.00224	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MC1R—skin cancer	0.000292	0.00219	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000288	0.00216	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—MC1R—skin cancer	0.000286	0.00214	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—PTCH1—skin cancer	0.000284	0.00213	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—SMO—skin cancer	0.000284	0.00213	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—PTGER4—skin cancer	0.000276	0.00207	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CSPG4—skin cancer	0.000275	0.00207	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—CDK4—skin cancer	0.000273	0.00205	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—SHH—skin cancer	0.00027	0.00202	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTCH2—skin cancer	0.000269	0.00201	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—SHH—skin cancer	0.000266	0.002	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTCH2—skin cancer	0.000265	0.00199	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—SMO—skin cancer	0.000256	0.00192	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—PTCH1—skin cancer	0.000256	0.00192	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—PTCH1—skin cancer	0.000252	0.00189	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—SMO—skin cancer	0.000252	0.00189	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—PTGER4—skin cancer	0.000249	0.00187	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000247	0.00185	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—CDK4—skin cancer	0.000246	0.00184	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—PTGER4—skin cancer	0.000246	0.00184	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RHOU—skin cancer	0.000245	0.00184	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—CDK4—skin cancer	0.000243	0.00182	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTCH2—skin cancer	0.000239	0.00179	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—MC1R—skin cancer	0.000238	0.00178	CbGpPWpGaD
L-DOPA—PSIP1—Disease—BRAF—skin cancer	0.000237	0.00178	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL6—skin cancer	0.000225	0.00168	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MC1R—skin cancer	0.000216	0.00162	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—MC1R—skin cancer	0.000214	0.0016	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PTGER4—skin cancer	0.000212	0.00159	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—MC1R—skin cancer	0.000211	0.00158	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SHH—skin cancer	0.000208	0.00156	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SHH—skin cancer	0.000204	0.00153	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH2—skin cancer	0.000203	0.00152	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—NRAS—skin cancer	0.000201	0.0015	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—skin cancer	0.0002	0.0015	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SMO—skin cancer	0.000197	0.00148	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTCH1—skin cancer	0.000197	0.00148	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MC1R—skin cancer	0.000194	0.00146	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTCH1—skin cancer	0.000193	0.00145	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SMO—skin cancer	0.000193	0.00145	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTGER4—skin cancer	0.000192	0.00144	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MC1R—skin cancer	0.000192	0.00144	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTGS2—skin cancer	0.000191	0.00143	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTGER4—skin cancer	0.000188	0.00141	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ENO2—skin cancer	0.000187	0.0014	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CDK4—skin cancer	0.000186	0.00139	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—IL6—skin cancer	0.000183	0.00138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GLI2—skin cancer	0.000181	0.00136	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH2—skin cancer	0.000176	0.00132	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—NRAS—skin cancer	0.000175	0.00131	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MC1R—skin cancer	0.000173	0.00129	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—KRAS—skin cancer	0.000173	0.00129	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GLI1—skin cancer	0.00017	0.00128	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—MC1R—skin cancer	0.000161	0.00121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SUFU—skin cancer	0.000161	0.00121	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH2—skin cancer	0.000159	0.00119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH2—skin cancer	0.000157	0.00117	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PTGER4—skin cancer	0.000156	0.00117	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SHH—skin cancer	0.000154	0.00115	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—skin cancer	0.000153	0.00115	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—KRAS—skin cancer	0.000151	0.00113	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NRAS—skin cancer	0.000149	0.00112	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—skin cancer	0.000147	0.0011	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MC1R—skin cancer	0.000147	0.0011	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SMO—skin cancer	0.000146	0.00109	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTCH1—skin cancer	0.000146	0.00109	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTGER4—skin cancer	0.000142	0.00106	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PTGER4—skin cancer	0.000141	0.00105	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PTGER4—skin cancer	0.000139	0.00104	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SHH—skin cancer	0.000138	0.00104	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SHH—skin cancer	0.000137	0.00102	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—skin cancer	0.000134	0.001	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GLI2—skin cancer	0.000134	0.001	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTCH1—skin cancer	0.000131	0.000984	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SMO—skin cancer	0.000131	0.000984	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SMO—skin cancer	0.000129	0.000971	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTCH1—skin cancer	0.000129	0.000971	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KRAS—skin cancer	0.000128	0.00096	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—skin cancer	0.000128	0.00096	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTGER4—skin cancer	0.000128	0.000958	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MC1R—skin cancer	0.000127	0.000956	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTGER4—skin cancer	0.000126	0.000945	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GLI1—skin cancer	0.000126	0.000942	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SHH—skin cancer	0.000123	0.000923	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RASA1—skin cancer	0.000122	0.000917	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GLI2—skin cancer	0.00012	0.000902	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH2—skin cancer	0.00012	0.000898	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SUFU—skin cancer	0.000119	0.000893	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GLI2—skin cancer	0.000119	0.00089	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTCH1—skin cancer	0.000117	0.000875	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMO—skin cancer	0.000117	0.000875	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—skin cancer	0.000116	0.000871	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MC1R—skin cancer	0.000115	0.00086	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTGER4—skin cancer	0.000114	0.000851	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MC1R—skin cancer	0.000113	0.000849	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GLI1—skin cancer	0.000113	0.000848	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GLI1—skin cancer	0.000112	0.000837	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—skin cancer	0.000109	0.000816	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ERCC2—skin cancer	0.000109	0.000816	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SUFU—skin cancer	0.000107	0.000804	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—skin cancer	0.000106	0.000798	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PTGER4—skin cancer	0.000106	0.000796	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SUFU—skin cancer	0.000106	0.000793	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—skin cancer	0.000105	0.000784	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SHH—skin cancer	0.000104	0.000783	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—skin cancer	0.000104	0.000781	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—skin cancer	0.000103	0.000774	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FOXO4—skin cancer	0.0001	0.000752	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH1—skin cancer	9.91e-05	0.000743	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SMO—skin cancer	9.91e-05	0.000743	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTGER4—skin cancer	9.64e-05	0.000723	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—skin cancer	9.58e-05	0.000718	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—skin cancer	9.45e-05	0.000708	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SHH—skin cancer	9.08e-05	0.000681	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GLI2—skin cancer	9.08e-05	0.000681	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RASA1—skin cancer	9.02e-05	0.000677	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MC1R—skin cancer	8.66e-05	0.000649	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH1—skin cancer	8.61e-05	0.000645	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMO—skin cancer	8.61e-05	0.000645	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GLI1—skin cancer	8.54e-05	0.00064	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTGER4—skin cancer	8.38e-05	0.000628	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SHH—skin cancer	8.18e-05	0.000613	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RASA1—skin cancer	8.12e-05	0.000609	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SUFU—skin cancer	8.09e-05	0.000607	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SHH—skin cancer	8.07e-05	0.000605	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RASA1—skin cancer	8.02e-05	0.000601	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—skin cancer	7.9e-05	0.000592	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLIN2—skin cancer	7.86e-05	0.000589	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH1—skin cancer	7.75e-05	0.000581	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMO—skin cancer	7.75e-05	0.000581	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMO—skin cancer	7.65e-05	0.000573	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH1—skin cancer	7.65e-05	0.000573	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTGER4—skin cancer	7.54e-05	0.000566	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTGER4—skin cancer	7.44e-05	0.000558	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FOXO4—skin cancer	7.4e-05	0.000555	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—skin cancer	7.23e-05	0.000542	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TERT—skin cancer	6.7e-05	0.000502	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FOXO4—skin cancer	6.66e-05	0.0005	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FOXO4—skin cancer	6.58e-05	0.000493	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—skin cancer	6.52e-05	0.000489	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CSPG4—skin cancer	6.33e-05	0.000475	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SHH—skin cancer	6.17e-05	0.000463	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RASA1—skin cancer	6.13e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMO—skin cancer	5.85e-05	0.000439	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH1—skin cancer	5.85e-05	0.000439	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTGER4—skin cancer	5.7e-05	0.000427	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—skin cancer	5.64e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—BRAF—skin cancer	5.31e-05	0.000398	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FOXO4—skin cancer	5.03e-05	0.000377	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—skin cancer	4.94e-05	0.000371	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—skin cancer	4.86e-05	0.000364	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—skin cancer	4.45e-05	0.000334	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—skin cancer	4.39e-05	0.000329	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—skin cancer	4.31e-05	0.000323	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—skin cancer	4.17e-05	0.000312	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—skin cancer	4.13e-05	0.00031	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—skin cancer	3.95e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—skin cancer	3.92e-05	0.000294	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—skin cancer	3.75e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—skin cancer	3.7e-05	0.000277	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—skin cancer	3.59e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—skin cancer	3.53e-05	0.000264	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—skin cancer	3.48e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—skin cancer	3.36e-05	0.000252	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—skin cancer	3.33e-05	0.00025	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—skin cancer	3.23e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—skin cancer	3.18e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—skin cancer	3.05e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—skin cancer	2.92e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—skin cancer	2.87e-05	0.000215	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—skin cancer	2.83e-05	0.000212	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—skin cancer	2.74e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—skin cancer	2.71e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—skin cancer	2.66e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—skin cancer	2.63e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—skin cancer	2.59e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—skin cancer	2.55e-05	0.000191	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—skin cancer	2.5e-05	0.000188	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—skin cancer	2.46e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—skin cancer	2.44e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—skin cancer	2.44e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—skin cancer	2.33e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—skin cancer	2.22e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—skin cancer	2.19e-05	0.000164	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—skin cancer	2.12e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—skin cancer	2.07e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—skin cancer	1.98e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—skin cancer	1.91e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—skin cancer	1.88e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—skin cancer	1.88e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—skin cancer	1.8e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—skin cancer	1.72e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—skin cancer	1.69e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—skin cancer	1.67e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—skin cancer	1.67e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—skin cancer	1.62e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—skin cancer	1.6e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—skin cancer	1.55e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—skin cancer	1.53e-05	0.000115	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—skin cancer	1.5e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—skin cancer	1.44e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—skin cancer	1.28e-05	9.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—skin cancer	1.22e-05	9.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—skin cancer	1.17e-05	8.78e-05	CbGpPWpGaD
